Literature DB >> 19910139

Melanoma metastases to the neck nodes: role of adjuvant irradiation.

Primoz Strojan1, Boris Jancar, Maja Cemazar, Maja Pohar Perme, Marko Hocevar.   

Abstract

PURPOSE: To review experiences in the treatment of regionally advanced melanoma to the neck and/or parotid with emphasis on the role of adjuvant radiotherapy. PATIENTS AND METHODS: Clinical and histopathologic data, treatment details, and outcomes in patients treated during the period 2000-2006 at the Institute of Oncology, Ljubljana, Slovenia, were reviewed.
RESULTS: A total of 40 patients with 42 dissections underwent surgery, and 43 patients with 45 dissections received irradiation postoperatively to a median equivalent dose (eqTD(2): 2 Gy/fraction, 1 fraction/day, 5 fractions/week) of 60 Gy (range, 47.8-78.8). Regional control 2 years after surgery was 56% (95% confidence interval [CI] 40-72%) and after postoperative radiotherapy 78% (CI 63-92%) (p = 0.015). On multivariate analysis, postoperative radiotherapy (yes vs. no: hazard ratio [HR] 6.3, CI 2.0-20.6) and sum of the risk factors present (i.e., risk factor score; HR 1.7 per score point, CI 1.2-2.6) were predictive for regional control. On logistic regression testing, the number of involved nodes was associated with the probability of distant metastases (p = 0.021). The incidence of late toxicity did not correlate with the mode of therapy, eqTD(2), or fractionation pattern.
CONCLUSIONS: Adjuvant radiotherapy has the potential to compensate effectively for the negative impact of adverse histopatologic features to disease control in a dissected nodal basin. More conventionally fractionated radiotherapy regimens using fraction doses of 2-2.5 Gy, with cumulative eqTD(2)> or =60 Gy, are recommended. The number of involved lymph nodes is proposed as an additional criterion for limiting the implementation of adjuvant irradiation. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19910139     DOI: 10.1016/j.ijrobp.2009.06.071

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  A retrospective analysis of the role of adjuvant radiotherapy in the treatment of cutaneous melanoma.

Authors:  Aaron Baker; Fabian Camacho; Genevieve Andrews; Heath Mackley
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

Review 2.  Adjuvant Therapy for Melanoma.

Authors:  Aya Agha; Ahmad A Tarhini
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

Review 3.  [Malignant head and neck melanoma: Part 2: Therapy].

Authors:  C Pföhler; T Vogt; C S L Müller
Journal:  HNO       Date:  2015-08       Impact factor: 1.284

Review 4.  Update on primary head and neck mucosal melanoma.

Authors:  Fernando López; Juan P Rodrigo; Antonio Cardesa; Asterios Triantafyllou; Kenneth O Devaney; William M Mendenhall; Missak Haigentz; Primož Strojan; Phillip K Pellitteri; Carol R Bradford; Ashok R Shaha; Jennifer L Hunt; Remco de Bree; Robert P Takes; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2015-05-22       Impact factor: 3.147

5.  Role of radiotherapy in melanoma management.

Authors:  Primoz Strojan
Journal:  Radiol Oncol       Date:  2010-03-18       Impact factor: 2.991

6.  Adjuvant radiation therapy in metastatic lymph nodes from melanoma.

Authors:  Jean-Emmanuel Bibault; Sylvain Dewas; Xavier Mirabel; Laurent Mortier; Nicolas Penel; Luc Vanseymortier; Eric Lartigau
Journal:  Radiat Oncol       Date:  2011-02-06       Impact factor: 3.481

7.  BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.

Authors:  Adam R Wolfe; Priyanka Chablani; Michael R Siedow; Eric D Miller; Steve Walston; Kari L Kendra; Evan Wuthrick; Terence M Williams
Journal:  Radiat Oncol       Date:  2021-09-18       Impact factor: 3.481

Review 8.  Multidisciplinary Care of BRAF-Mutant Stage III Melanoma: A Physicians Perspective Review.

Authors:  Lynn A Cornelius; Ryan C Fields; Ahmad Tarhini
Journal:  Oncologist       Date:  2021-06-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.